keyword
https://read.qxmd.com/read/38345252/comparative-efficacy-of-p-cabs-versus-proton-pump-inhibitors-for-grade-c-d-esophagitis-a-systematic-review-and-network-meta-analysis
#1
JOURNAL ARTICLE
Qianjun Zhuang, Songfeng Chen, Xuyu Zhou, Xingyu Jia, Mengyu Zhang, Niandi Tan, Fangfei Chen, Zhanye Zhang, Junnan Hu, Yinglian Xiao
BACKGROUND: s and Aims: Los Angeles (LA) grade C/D esophagitis is a severe manifestation of GERD that require active treatment and close follow-up. Potassium competitive acid blockers (P-CABs) are promising alternatives to proton-pump inhibitors (PPIs). We aimed to compare the efficacy and safety of P-CABs and PPIs in healing Grade C/D esophagitis to aid clinical decision-making. METHODS: A systematic literature search was performed using PubMed, MEDLINE, Cochrane Central Register of Controlled Trials...
February 12, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38279248/the-effect-of-dexlansoprazole-on-gastroesophageal-reflux-disease-a-systematic-review-and-meta-analysis
#2
REVIEW
Gabriel Pereira Nunes, Thayná Cerqueira Silveira, João Vítor Silveira Marciano, Alexandre Henrique Dos Reis-Prado, Tulio Morandin Ferrisse, Evandro Barbosa Dos Anjos, Maria Helena Fernandes
This systematic review and meta-analysis evaluated the efficacy of dexlansoprazole (a proton pump inhibitor-PPI) in resolving heartburn, reflux, and other symptoms and complications resulting from gastroesophageal reflux disease (GERD). The study followed PRISMA 2020 and was registered in PROSPERO (CRD42020206513). The search strategy used MeSH and free terms appropriately adapted for each database. Only randomized clinical trials (RCTs) were included. The Cochrane tool (RoB 2.0) was used to assess the risk of bias, and the certainty of evidence was rated using GRADE...
January 19, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38049205/acid-suppressive-drugs-a-systematic-review-and-network-meta-analysis-of-their-nocturnal-acid-inhibitory-effect
#3
JOURNAL ARTICLE
Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Minghui Sun
BACKGROUND AND AIMS: Acid-suppressive drugs (ASDs) are widely used in many gastric acid-associated diseases. Nocturnal acid breakthrough has been a common problem of many ASDs, such as proton-pump inhibitors (PPIs) and H2 -receptor antagonists (H2RAs). Potassium-competitive acid blockers (P-CABs) are expected to solve this continuing conundrum. This article examined major ASDs and compared them with placebo in terms of nocturnal acid-inhibitory effects, using a network meta-analysis of randomized controlled trials (RCTs)...
December 4, 2023: Pharmacotherapy
https://read.qxmd.com/read/37232568/improving-clinical-outcomes-of-barrett-s-esophagus-with-high-dose-proton-pump-inhibitors-and-cryoablation
#4
JOURNAL ARTICLE
Harry Snady
INTRODUCTION: Esophageal adenocarcinoma incidence has increased significantly despite surveillance endoscopy for Barrett's esophagus (BE) and gastric acid supression medications. This prospective, cohort study's aims were to determine the long-term efficacy of proton-pump inhibitors twice daily (PPI-BID) with cryotherapy (CRYO) for complete ablation of BE. MATERIALS AND METHODS: Consecutive BE patients were managed with a PPI-BID, CRYO ablation, follow-up protocol...
December 2023: Annals of Medicine
https://read.qxmd.com/read/37210931/protective-effects-of-esomeprazole-against-cisplatin-induced-ototoxicity-an-in-vitro-and-in-vivo-study
#5
JOURNAL ARTICLE
Hanul Jeon, In Sik Song, Jin-Gyeong Park, Hyejin Lee, Eunjung Han, Saemi Park, Yunkyoung Lee, Chi-Man Song, Wooyoung Hur, In-Gyun Lee, June Choi
In this study, we aimed to identify novel compounds that could afford protection against cisplatin-induced ototoxicity by employing both cell- and zebrafish (Danio rerio)-based screening platforms. We screened 923 US Food and Drug Administration-approved drugs to identify potential compounds exhibiting protective effects against cisplatin-induced ototoxicity in HEI-OC1 cells (auditory hair cell line). The screening strategy identified esomeprazole and dexlansoprazole as the primary hit compounds. Subsequently, we examined the effects of these compounds on cell viability and apoptosis...
July 2023: Aquatic Toxicology
https://read.qxmd.com/read/37189702/intraluminal-therapy-for-helicobacter-pylori-infection-comparison-of-medicament-containing-tetracycline-metronidazole-and-bismuth-versus-amoxicillin-metronidazole-and-clarithromycin-a-randomized-controlled-study
#6
JOURNAL ARTICLE
Ting-Wen Liu, Yen-Po Chen, Cheng-Yu Ho, Ming-Jen Chen, Horng-Yuan Wang, Shou-Chuan Shih, Tai-Cherng Liou
Helicobacter pylori (H. pylori) can be eradicated immediately via local application of single-dose medicament on endoscopic examination. In our previous report, "the eradication rate of intraluminal therapy for H. pylori infection (ILTHPI) is 53.7% (51/95) using medicament containing amoxicillin, metronidazole, and clarithromycin". We aimed to evaluate the efficacy and adverse events of medicament containing tetracycline, metronidazole, and bismuth and to improve the efficacy of stomach acid control before ILTHPI...
April 3, 2023: Biomedicines
https://read.qxmd.com/read/36986786/evaluation-of-in-vitro-and-in-vivo-antiviral-activities-of-vitamin-d-for-sars-cov-2-and-variants
#7
JOURNAL ARTICLE
Chee-Keng Mok, Yan Ling Ng, Bintou Ahmadou Ahidjo, Zhen Qin Aw, Huixin Chen, Yi Hao Wong, Regina Ching Hua Lee, Marcus Wing Choy Loe, Jing Liu, Kai Sen Tan, Parveen Kaur, De Yun Wang, Erwei Hao, Xiaotao Hou, Yong Wah Tan, Jiagang Deng, Justin Jang Hann Chu
The COVID-19 pandemic has brought about unprecedented medical and healthcare challenges worldwide. With the continual emergence and spread of new COVID-19 variants, four drug compound libraries were interrogated for their antiviral activities against SARS-CoV-2. Here, we show that the drug screen has resulted in 121 promising anti-SARS-CoV-2 compounds, of which seven were further shortlisted for hit validation: citicoline, pravastatin sodium, tenofovir alafenamide, imatinib mesylate, calcitriol, dexlansoprazole, and prochlorperazine dimaleate...
March 12, 2023: Pharmaceutics
https://read.qxmd.com/read/36909115/eosinophilic-esophagitis-in-a-75-year-old-saudi-man-a-case-report
#8
Saad S Alkhowaiter
The incidence and prevalence of eosinophilic esophagitis (EoE) are increasing in adults and children worldwide. Once thought primarily to affect children and young adults, EoE is now recognized in all age groups. To our knowledge, this case study is the first known report of EoE diagnosed in an elderly man in Saudi Arabia. The 75-year-old patient presented with a chief complaint of dry mouth and mild heartburn symptoms. Further history inquiry disclosed that he experienced dysphagia occasionally. His endoscopy findings revealed signs associated with EoE, which was confirmed by biopsy showing marked infiltration of eosinophils (>30/hpf) in upper and lower esophagus...
February 2023: Curēus
https://read.qxmd.com/read/36773006/trends-in-prescribing-volumes-and-costs-of-proton-pump-inhibitors-in-three-outpatient-specialties-a-three-year-retrospective-study-in-a-tertiary-hospital-in-thailand
#9
JOURNAL ARTICLE
Fitriya Yusof, Siriprapha Sanguanhong, Suchada Soorapan, Juraporn Pongwecharak
OBJECTIVES: The study determined a comparative three-year trend in prescribing volumes and costs of proton pump inhibitors in three outpatient specialties of a tertiary hospital. METHODS: Prescription data for three consecutive fiscal years (2016-2018) were extracted from a tertiary hospital electronic database, for the gastrointestinal, cardiovascular and orthopaedic outpatient specialties. The data collected were individual proton pump inhibitors, overall and individual prescribing volumes (capsule/tablet) and costs, stratified by specialty and fiscal year...
March 13, 2023: International Journal of Pharmacy Practice
https://read.qxmd.com/read/36317518/comparison-of-pharmacodynamics-between-tegoprazan-and-dexlansoprazole-regarding-nocturnal-acid-breakthrough-a-randomized-crossover-study
#10
RANDOMIZED CONTROLLED TRIAL
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae
BACKGROUND/AIMS: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough in healthy subjects. METHODS: In a randomized, open-label, single-dose, balanced incomplete block crossover study, 24 healthy male volunteers were enrolled and randomized to receive oral tegoprazan (50, 100, or 200 mg) or dexlansoprazole (60 mg) during each of two administration periods, separated by a 7- to 10-day washout period...
January 15, 2023: Gut and Liver
https://read.qxmd.com/read/36153790/comparison-of-acid-lowering-drugs-for-endoscopy-negative-reflux-disease-systematic-review-and-network-meta-analysis
#11
JOURNAL ARTICLE
Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J Black, Alexander C Ford
BACKGROUND: The comparative efficacy and safety of medical therapies for gastro-esophageal reflux symptoms in endoscopy-negative reflux disease is unclear. We conducted a network meta-analysis to evaluate efficacy and safety of proton pump inhibitors (PPIs), histamine-2-receptor antagonists, potassium-competitive acid blockers (PCABs), and alginates in patients with endoscopy-negative reflux disease. METHODS: We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane central register of controlled trials from inception to February 1, 2022...
January 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/36150104/suppression-of-vacuolar-type-atpase-and-induction-of-endoplasmic-reticulum-stress-by-proton-pump-inhibitors
#12
JOURNAL ARTICLE
Wei-Ping Lee
BACKGROUND: Proton pump inhibitors (PPIs), such as esomeprazole, pantoprazole, dexlansoprazole, and rabeprazole, are one of the most commonly prescribed medications. Several studies have linked the long-term use of PPIs to a potentially increased risk of gastric cancer. Therefore, this study aimed to determine the underlying mechanism of PPI-mediated gastric cancer. METHODS: Lysosomes were isolated using immunoprecipitation. The inhibition of vacuolar-type ATPase (V-ATPase) by PPIs was assayed using a PiColorLock Gold Phosphate Detection System...
September 1, 2022: Journal of the Chinese Medical Association: JCMA
https://read.qxmd.com/read/36142643/proton-pump-inhibitors-and-bone-health-an-update-narrative-review
#13
REVIEW
Eric Lespessailles, Toumi Hechmi
Proton pump inhibitors (PPIs) are an antacid drug often used in acid-related disorders. They decrease acid secretion in the stomach by blocking an enzyme called H+/K+ ATPase which controls acid production. Introduced to the market in 1989, their use has increased rapidly worldwide and they are now among the top 10 most prescribed drugs in the United States. As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole)...
September 14, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/36105026/dexlansoprazole-prevents-pulmonary-artery-hypertension-by-inhibiting-pulmonary-artery-smooth-muscle-cell-to-fibroblast-transition
#14
JOURNAL ARTICLE
Qian Jiao, Fangdi Zou, Shiliang Li, Jiawen Wang, Yunping Xiao, Zhihua Guan, Liang Dong, Jinwei Tian, Shengqing Li, Rui Wang, Jian Zhang, Honglin Li
OBJECTIVES: To validate that dexlansoprazole, an anti-acid drug, can prevent pulmonary artery hypertension (PAH) in preclinical animal models and find the possible mechanism of action of dexlansoprazole for this new indication. METHODS: The efficacy of dexlansoprazole to attenuate PAH in vivo was evaluated in PAH animal models. Plasma guanosine 3', 5'-cyclic phosphate (cGMP) in PAH rats was measured by enzyme linked immunosorbent assay (ELISA). To investigate the anti-PAH effect of dexlansoprazole in vitro, proliferation and migration assays of primary cultured pulmonary artery smooth muscle cells (PASMCs) were performed...
2022: American Journal of Translational Research
https://read.qxmd.com/read/35907469/deciphering-the-nature-of-binding-of-dexlansoprazole-with-dna-biophysical-and-docking-approaches
#15
JOURNAL ARTICLE
Anna Tanuja Safala Bodapati, Bijaya Ketan Sahoo, Ragaiahgari Srinivas Reddy, Kandikonda Lavanya, Shravya Rao Madku
Drugs, in general, exhibit their pharmacological activity in binding with intracellular targets. Numerous anticancer and antibacterial drugs target DNA as one of their primary intracellular targets. Dexlansoprazole (DLP) is a heterocyclic compound containing benzimidazole moiety and a proton pump inhibitor used to treat gastroesophageal reflux disease. The interaction of dexlansoprazole with calf thymus DNA (ct-DNA) has been studied using biophysical methods. The UV-Visible studies revealed a binding constant of 2...
July 27, 2022: International Journal of Biological Macromolecules
https://read.qxmd.com/read/35787720/an-update-on-drug-drug-interactions-associated-with-proton-pump-inhibitors
#16
REVIEW
Inès Ben Ghezala, Maxime Luu, Marc Bardou
INTRODUCTION: Proton pump inhibitors (PPIs) block the gastric H/K-ATPase, therefore inhibiting acid gastric secretion, leading to an increased pH (>4). They account for an extremely high number of prescriptions worldwide. Numerous drug-drug interactions have been described with PPIs, but all the described interactions do not have clinical significance. AREAS COVERED: This review will discuss the latest updates on drug-drug interactions with PPIs, focusing on the last 10-year publications in the following areas: anti-infective agents, anticancer drugs, antiplatelet agents and anticoagulants, and antidiabetics...
May 2022: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/35771390/nocturnal-acid-breakthrough-and-esophageal-acidification-during-treatment-with-dexlansoprazole-as-compared-to-omeprazole-in-patients-with-gastroesophageal-reflux-disease
#17
JOURNAL ARTICLE
Uday C Ghoshal, Arjun Blaachandran, Sushmita Rai, Asha Misra
BACKGROUND: Nocturnal acid breakthrough (NAB) may differ based on duration of proton pump inhibitor (PPI) action and Helicobacter pylori (H. pylori) infection; NAB may influence esophageal acidification (EA) and mucosal damage. Dexlansoprazole, a long-acting PPI, was not compared with omeprazole for NAB, gastric acid suppression, and EA in relation to H. pylori infection. METHODS: In this prospective open-label comparative observational study, gastroesophageal reflux disease (GERD) patients were evaluated using 24-h dual-channel pH-impedance monitoring while on dexlansoprazole (60 mg, n = 39) and omeprazole (20 mg, n = 41) to study the degree of gastric acid suppression, esophageal acid exposure, and NAB (primary outcome measures)...
August 2022: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://read.qxmd.com/read/35590283/syndrome-of-inappropriate-antidiuretic-hormone-secretion-is-associated-with-different-proton-pump-inhibitor-use-a-pharmacovigilance-study
#18
JOURNAL ARTICLE
Mengmeng Wang, Lingjian Zhang, Min Jia, Junyan Wang, Zhiwen Shen, Shuyue Wang, Xinghui Zhang, Jing Xu, Zheng Zheng, Xuanrui Lv, Xiaoyu Zong, Hui Li, Jin Zhou, Tong Meng, Mingzhu Chen, Bin Zhao, Jian Gong
AIM: The objective of this study was to evaluate the reported associations between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a variety of proton pump inhibitors (PPI) through analysis of the reports extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: FAERS reports from January 2004 to March 2020 were used to conduct disproportionality and Bayesian analyses. The definition of SIADH relied on the preferred terms provided by the Medical Dictionary for Regulatory Activities...
May 19, 2022: BMC Nephrology
https://read.qxmd.com/read/35536912/addendum-dexlansoprazole-for-gerd
#19
COMMENT
(no author information available yet)
No abstract text is available yet for this article.
May 16, 2022: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/35348553/comparison-tables-h2-receptor-antagonists-and-ppis
#20
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 4, 2022: Medical Letter on Drugs and Therapeutics
keyword
keyword
171825
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.